I've been here 6 years ....... but your approach Hobbit is the...

I've been here 6 years ....... but your approach Hobbit is the better. The lesson learnt is only to invest in micro biotech WHEN the company is on the verge of sustainable revenue and actual deals ....... which is where I believe CDY is at the moment.

The revenue side of the company speaks for itself with respect to OTC products. Yesterday's largely unsung news on cxbladder monitor's statistics is also money in the bank because the niche clinical application of that test is extremely clear (whereas cxbladder detect, while useful, remains in the fuzzy zone).

Deals deals deals. Without a stable, reproducable and safe monoclonal antibody cell line (to show) any deal done would be an extremely poor one. Still, to get an exceptional deal on this, CDY needs to put its share into Phase 1/ Phase II clinical trial(s) and for that, the company needs cash .... lots of cash. OK the strategy is realigned (we don't know the details) and we now have a company structure to accommodate the required deals so we await an announcement on it all. Back to Hobbit's timeframe ..... the absolute deadline on this has to be 2 weeks prior to option expiry (preferably a month or two earlier) .... otherwise I can't see how CDY could pay for its fair share s and thus monetarise the value of the IP. CRs won't do it and Maria has said that a CR is not planned ......... so we wait a little bit longer.

cheers